Baseline characteristics by COVID-19 vaccination status and death due to COVID-19
| Characteristic . | COVID-19 vaccination status . | Death due to COVID-19 . | ||
|---|---|---|---|---|
| No vaccination (n = 427) . | Vaccinated (n = 372) . | No COVID-19 death (n = 767)∗ . | COVID-19 death (n = 32)† . | |
| Age, y | ||||
| Mean (SD) | 59.6 (9.95) | 60.1 (8.89) | 59.8 (9.48) | 59.3 (9.32) |
| Median (range) | 60.0 (26-84) | 61.0 (32-82) | 61.0 (26-84) | 60.5 (37-78) |
| Age group, n (%) | ||||
| ≥65 y | 134 (31.4) | 117 (31.5) | 243 (31.7) | 8 (25.0) |
| ≥75 y | 24 (5.6) | 12 (3.2) | 34 (4.4) | 2 (6.3) |
| Geographical region, n (%) | ||||
| Africa‡ | 15 (3.5) | 5 (1.3) | 18 (2.3) | 2 (6.3) |
| East Asia§ | 15 (3.5) | 10 (2.7) | 24 (3.1) | 1 (3.1) |
| Eastern Europe‖ | 208 (48.7) | 132 (35.5) | 321 (41.9) | 19 (59.4) |
| Middle East¶ | 5 (1.2) | 1 (0.3) | 6 (0.8) | 0 |
| North America# | 76 (17.8) | 59 (15.9) | 132 (17.2) | 3 (9.4) |
| Oceania∗∗ | 23 (5.4) | 35 (9.4) | 58 (7.6) | 0 |
| South America†† | 25 (5.9) | 28 (7.5) | 48 (6.3) | 5 (15.6) |
| Western Europe‡‡ | 60 (14.1) | 102 (27.4) | 160 (20.9) | 2 (6.3) |
| BMI >30 kg/m2, n (%) | 96 (22.5) | 83 (22.3) | 167 (21.8) | 12 (37.5) |
| ECOG PS ≤1, n (%) | 379 (88.8) | 355 (95.4) | 706 (92.0) | 28 (87.5) |
| Bulky disease, n (%) | ||||
| ≥5 cm | 170 (39.8) | 140 (37.6) | 291 (37.9) | 19 (59.4) |
| ≥10 cm | 37 (8.7) | 19 (5.1) | 51 (6.6) | 5 (15.6) |
| Unmutated IGHV, n (%) | 261 (61.1) | 197 (53.0) | 438 (57.1) | 20 (62.5) |
| CIRS-G total score category, n (%) | ||||
| 0 | 91 (21.3) | 64 (17.2) | 147 (19.2) | 8 (25.0) |
| 1-6 | 334 (78.2) | 306 (82.3) | 616 (80.3) | 24 (75.0) |
| >6 | 2 (0.5) | 2 (0.5) | 4 (0.5) | 0 |
| B symptoms, n (%) | ||||
| Weight loss | 44 (10.3) | 30 (8.1) | 69 (9.0) | 5 (15.6) |
| Fever | 6 (1.4) | 5 (1.3) | 11 (1.4) | 0 |
| Night sweats | 209 (48.9) | 124 (33.3) | 312 (40.7) | 21 (65.6) |
| All of the above | 1 (0.2) | 2 (0.5) | 3 (0.4) | 0 |
| Any of the above | 219 (51.3) | 136 (36.6) | 334 (43.5) | 21 (65.6) |
| Characteristic . | COVID-19 vaccination status . | Death due to COVID-19 . | ||
|---|---|---|---|---|
| No vaccination (n = 427) . | Vaccinated (n = 372) . | No COVID-19 death (n = 767)∗ . | COVID-19 death (n = 32)† . | |
| Age, y | ||||
| Mean (SD) | 59.6 (9.95) | 60.1 (8.89) | 59.8 (9.48) | 59.3 (9.32) |
| Median (range) | 60.0 (26-84) | 61.0 (32-82) | 61.0 (26-84) | 60.5 (37-78) |
| Age group, n (%) | ||||
| ≥65 y | 134 (31.4) | 117 (31.5) | 243 (31.7) | 8 (25.0) |
| ≥75 y | 24 (5.6) | 12 (3.2) | 34 (4.4) | 2 (6.3) |
| Geographical region, n (%) | ||||
| Africa‡ | 15 (3.5) | 5 (1.3) | 18 (2.3) | 2 (6.3) |
| East Asia§ | 15 (3.5) | 10 (2.7) | 24 (3.1) | 1 (3.1) |
| Eastern Europe‖ | 208 (48.7) | 132 (35.5) | 321 (41.9) | 19 (59.4) |
| Middle East¶ | 5 (1.2) | 1 (0.3) | 6 (0.8) | 0 |
| North America# | 76 (17.8) | 59 (15.9) | 132 (17.2) | 3 (9.4) |
| Oceania∗∗ | 23 (5.4) | 35 (9.4) | 58 (7.6) | 0 |
| South America†† | 25 (5.9) | 28 (7.5) | 48 (6.3) | 5 (15.6) |
| Western Europe‡‡ | 60 (14.1) | 102 (27.4) | 160 (20.9) | 2 (6.3) |
| BMI >30 kg/m2, n (%) | 96 (22.5) | 83 (22.3) | 167 (21.8) | 12 (37.5) |
| ECOG PS ≤1, n (%) | 379 (88.8) | 355 (95.4) | 706 (92.0) | 28 (87.5) |
| Bulky disease, n (%) | ||||
| ≥5 cm | 170 (39.8) | 140 (37.6) | 291 (37.9) | 19 (59.4) |
| ≥10 cm | 37 (8.7) | 19 (5.1) | 51 (6.6) | 5 (15.6) |
| Unmutated IGHV, n (%) | 261 (61.1) | 197 (53.0) | 438 (57.1) | 20 (62.5) |
| CIRS-G total score category, n (%) | ||||
| 0 | 91 (21.3) | 64 (17.2) | 147 (19.2) | 8 (25.0) |
| 1-6 | 334 (78.2) | 306 (82.3) | 616 (80.3) | 24 (75.0) |
| >6 | 2 (0.5) | 2 (0.5) | 4 (0.5) | 0 |
| B symptoms, n (%) | ||||
| Weight loss | 44 (10.3) | 30 (8.1) | 69 (9.0) | 5 (15.6) |
| Fever | 6 (1.4) | 5 (1.3) | 11 (1.4) | 0 |
| Night sweats | 209 (48.9) | 124 (33.3) | 312 (40.7) | 21 (65.6) |
| All of the above | 1 (0.2) | 2 (0.5) | 3 (0.4) | 0 |
| Any of the above | 219 (51.3) | 136 (36.6) | 334 (43.5) | 21 (65.6) |
BMI, body mass index; CIRS-G, cumulative illness rating scale–geriatric; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region genes; SD, standard deviation.
Among patients with no COVID-19 death, 364 (47.5%) had received a COVID-19 vaccination.
Among patients with COVID-19 death, 8 (25.0%) had received a COVID-19 vaccination.
Includes South Africa.
Includes China, Taiwan, and South Korea.
Includes Bulgaria, Czech Republic, Hungary, Poland, Russia, Slovakia, and Turkey.
Includes Saudi Arabia.
Includes Canada and the United States.
Includes Australia.
Includes Argentina and Brazil.
Includes Austria, Denmark, France, Germany, Israel, Italy, The Netherlands, Spain, Sweden, and the United Kingdom.